NYXH vs INSP vs JPM vs NVCR vs TNDM

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 8. 7x trailing P/E (47. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 8. 7x versus JPMorgan Chase & Co. at 16. 0x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: JPM returned +465. 8% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately 134% more volatile than JPM relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 47. 6x for Inspire Medical Systems, Inc. — 33. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. NYXH, INSP, NVCR, TNDM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NYXH (Healthcare) and INSP (Healthcare) and JPM (Financial Services) and NVCR (Healthcare) and TNDM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NYXH is a small-cap high-growth stock; INSP is a small-cap deep-value stock; JPM is a large-cap deep-value stock; NVCR is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock. JPM pays a dividend while NYXH, INSP, NVCR, TNDM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.